Acyclovir 1000 mg Injection
RxNorm 2263503
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 2263503 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: acyclovir 1000 mg Injection.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCDPrescribable
Semantic Clinical Drug (SCD):
Acyclovir 1000 mg Injection
(Atom ID: 12350814)
SYPrescribable
Synonym (SY):
Acyclovir (as acyclovir sodium) 1000 mg Injection
(Atom ID: 11845137)
PSNPrescribable
Prescribable Name (PSN):
Acyclovir 1000 mg Injection
(Atom ID: 11845136)
SYPrescribable
Synonym (SY):
Acycycloguanosine 1000 mg Injection
(Atom ID: 11802806)
Patient Education
Acyclovir Injection
Acyclovir injection is used to treat first-time or repeat outbreaks of herpes simplex (a herpes virus infection of the skin and mucus membranes) and to treat herpes zoster (shingles; a rash that can occur in people who have had chickenpox in the past) in people with weak immune systems. It is also used to treat first-time genital herpes outbreaks (a herpes virus infection that causes sores to form around the genitals and rectum from time to time) in people with normal immune systems. Acyclovir injection is used to treat herpes simplex encephalitis (brain infection with swelling caused by the herpes virus) and herpes infections in newborn infants. Acyclovir injection is in a class of antiviral medications called synthetic nucleoside analogues. It works by stopping the spread of the herpes virus in the body. Acyclovir injection will not cure genital herpes and may not stop the spread of genital herpes to other people.
[Learn More]
* Please review the disclaimer below.